Coloplast (COLO-B.CO) Stock Analysis & AI Equity Report
Coloplast (COLO-B.CO) overview
Coloplast (COLO-B.CO) stock analysis and AI equity research. For the latest completed financial year, 2025, Coloplast reported revenue of DKK 27,874m and operating profit of DKK 7,579m; the year-end share price was 543.00 DKK and market capitalisation was DKK 122,374m. Coloplast is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Coloplast's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-18. Data will be refreshed during report generation.
About Coloplast
Coloplast A/S develops and sells intimate healthcare products and related services for people with personal medical needs. Its main businesses include ostomy care, continence care, bowel care, wound and tissue repair, interventional urology, and voice and respiratory care. The company also offers support services for users and healthcare professionals.
Generate the Coloplast report
Coloplast is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Coloplast and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.